| Wenwu Wang,Shanshan Huang,Xiaoyan Huang,Yan Zhang,Xiaoyan Qi. Clinical observation of rh-endostatin combined with chemotherapy as first line treatment for metastatic colorectal cancer. Oncol Transl Med, 2016, 2: 279-284. |
| 重组人血管内皮抑制素联合化疗 一线治疗晚期转移性结直肠癌的疗效观察 |
| Clinical observation of rh-endostatin combined with chemotherapy as first line treatment for metastatic colorectal cancer |
| Received:June 16, 2016 Revised:November 22, 2016 |
| DOI：10.1007/s10330-016-0166-6 |
| 中文关键词: 重组人血管内皮抑制素注射液；FOLFOX4方案；转移性结直肠癌 |
| 英文关键词: rh-endostatin; FOLFOX4 regimen; metastatic colorectal cancer |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Wenwu Wang* | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Shanshan Huang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Xiaoyan Huang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Yan Zhang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Xiaoyan Qi | Department of Oncology,Central Hospital of Zibo，Communist Youth League Road 54 Zhangdian district, Zibo city, Shandong, 255036，China | 1275452403@qq.com |
|
| Hits: 9131 |
| Download times: 10545 |
| 中文摘要: |
| 目的 探讨重组人血管内皮抑制素（恩度）联合化疗一线治疗晚期转移性结直肠癌的疗效及安全性。方法 60例晚期转移性结直肠癌分为试验组（n=30）和对照组（n=30），对照组采用FOLFOX4化疗方案，试验组采用恩度联合FOLFOX4方案。结果 试验组和对照组获得的有效率（RR）分别为53.3%和36.7%（P＜0.05），疾病控制率（DCR）为85.5%和73.3%（P＜0.05），两组患者的中位无进展生存期（PFS）分别为7.3个月和5.3个月（ P＜0.05），中位总生存时间OS分别为11.6个月和9.3个月（P＜0.05）。对其中的27例肝转移患者进行亚组分析，研究表明试验组和对照组RR及DCR比较差异均有统计学意义（P＜0.05），但是PFS及OS无统计学意义（P＞0.05）。主要不良反应为血液学毒性、消化道反应、神经毒性等，多为I～II级；两组患者经化疗后QOL均得到较大程度的改善；与治疗前相比，治疗后CEA和CAl99均显著下降，且治疗后试验组下降较对照组更明显（P＜0.05）。结论 恩度联合化疗一线治疗晚期转移性结直肠癌安全有效。 |
| 英文摘要: |
| Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the
treatment of metastatic colorectal cancer.
Methods All 60 metastatic colorectal cancer patients were divided into the test group (n = 30) and the
control group (n = 30). The control group was treated with chemotherapy regime FOLFOX4 (Oxaliplatin
Fluorouracil Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4
scheme.
Results The response rates were 53.3% in test group and 36.7% in control group respectively (P < 0.05),
the disease control rate were 83.3% and 73.3% (P < 0.05). The median progression-free survival in test
group and control group were 7.3 months versus 5.3 months (P < 0.05) and median overall survival were
11.6 months versus 9.3 months (P < 0.05). Among 27 cases of liver metastases were sub group analysis,
difference on the test group and the control group response rate (RR) and disease control rate (DCR) had
statistical significance (P < 0.05), but difference on progression free survival (PFS) and overall survival
(OS) had no statistical significance (P > 0.05). The major toxicities were myelosuppression, gastrointestinal
symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life (QOL) of patients were more
improved than before treatment. After treatment the carcino embryonie antigen (CEA) and caner antigent
199 (CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the
control group.
Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer
is safer and effective, and also improves PFS. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|